BioSpace News Archive

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “TELO”) announces that it has completed the validation of a suite of proprietary automation tools developed using cutting-edge machine learning, deep machine learning and artificial intelligence technologies to maximize the efficiency and throughput of its technology workflow.

Under the terms of the share purchase agreement the Company has agreed to sell 100% of the securities of Pharmadrug GMBH for consideration consisting of 5,500,000 common shares in the capital of Khiron and a non-interest bearing promissory note in the principal amount of $1,100,000 which note will be payable one year from the date of issue.

Erbi Biosystems, Inc., a global leader in dose-scale, fully automated microbioreactors for cell therapy development and manufacturing, today announced the appointment of Brad Hamilton to the position of Chief Scientific Officer, effective immediately.

Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today it has expanded its relationship with a leading Contract Development and Manufacturing Organization (CDMO), in the development of advanced cell and gene therapies, to a preferred partnership.

NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has received a highly competitive Biomedical Catalyst (BMC) award to fund pre-clinical development of its novel small molecule disease-modifying medicines for the treatment of Parkinson’s disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders.

Following completion of the Sale of Assets to KemPharm, Orphazyme will no longer have any material ongoing operational business activities and KemPharm will retain all of Orphazyme’s remaining Danish employees, to continue the early access programs with arimoclomol, and to continue to pursue the potential approval of arimoclomol as a treatment option for NPC.

Mezzion Pharma Co., Ltd. (Mezzion Pharma) met with the FDA Division of Cardiology and Nephrology (DCN) on Friday, May 27th to discuss with the FDA the path forward for the regulatory approval of udenafil for the treatment of single ventricle heart disease (SVHD) in children with Fontan physiology.

PatientView is today publishing the results of its latest ‘Corporate Reputation of Pharma’ survey—cancer edition, now in its 9th year, and two years into the Covid-19 pandemic.

POXEL SA (Euronext: POXEL - FR0012432516), today announces that the Poxel team will participate in several upcoming investor and scientific conferences in June 2022.

The Lundquist Institute announced that it has received a grant of $112,000 from the Johnny Carson Foundation to support the training of the next generation of chronic obstructive pulmonary disease researchers at its Institute of Respiratory Medicine and Exercise Physiology, a world-leading venue for respiratory medicine research spanning basic and clinical science.